
|Videos|December 13, 2020
Analyzing an investigational ophthalmic solution for treating presbyopia-related symptoms
Author(s)David Hutton, Alex Delaney-Gesing
Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.
Advertisement
Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, an AbbVie company, discusses the results from a presentation titled, "Two Phase b Study Results for the Development of a Proprietary Formulation for the Treatment of Presbyopia," presented during the virtual AAO 2020 meeting.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The Atrophy Advisor: An online tool to inform GA treatment decisions
2
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
3
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease
4
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
5







































